Skip to main content
Staff Login
Username
*
Enter your The Contraceptive Pipeline Database username.
Password
*
Enter the password that accompanies your username.
Log in
Forgot password
Toggle navigation
Zavesca
Product Overview
Alternative Name:
Miglustat, N-butyldeoxynojirimycin (NB-DNJ)
Development Status:
Inactive
Target:
Male
Mode:
Non-hormonal
Delivery Type:
Oral
Duration Type:
Permanent
Description:
Zavesca, a medication already approved for treating a rare genetic disorder, works as a male contraceptive for a particular strain of laboratory mouse. Exactly how Zavesca acts as a contraceptive for the mice is not known.
Updated date:
May 30, 2018
Vertical Tabs
Product Details
Active Pharmaceutical Ingredient (API):
Miglustat
Potential Multi-Purpose Technology (MPT):
No
Partner:
University of Washington
,
Oxford GlycoSciences
Status
Project Phase:
Discovery
Status Details:
Research on Zavesca as a male contraceptive has stopped as it was shown to not be effective in humans.
Programmatic Considerations
Additional Information
Download Product Report
